Beatriz Birelli Do Nascimento
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Beatriz Birelli Do Nascimento has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Alan Maicon de Oliveira
School of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo Ribeirão Preto São Paulo Brazil
1 shared publication - Allan Oliveira Santos
Universidade Estadual de Campinas, Brazil
1 shared publication - Ana Carolina Figueiredo Modesto
Postgraduate Program in Pharmaceutical Sciences - University of Sorocaba, Sorocaba, Brazil
1 shared publication - Andreia Vicente
Nuclear Medicine and PET/CT, Sírio-Libanês Hospital, São Paulo, SP, Brazil
1 shared publication - Bianca Gianola Belline Silva
Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade de Sorocaba (UNISO), Sorocaba 18273-683, SP, Brazil
1 shared publication - Elba Etchebehere
Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas, Brazil
1 shared publication
Latest Publications
- Open Access
- 21 August 2026
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 48 (6) , 2201-2211
Instruments for assessing healthcare professionals’ knowledge, attitudes and practices regarding deprescribing: a scoping review
Introduction: Deprescribing is a multiprofessional process which aims to optimize medication use and improve patient safety, in which healthcare professionals' knowledge, attitudes, and practices (KAP) play a central role. The instruments used to assess KAP among nurses, pharmacists and physicians remain poorly characterised in terms of scope and measurement quality. Aim: To map and characterize the instruments used to assess healthcare professionals’ knowledge, attitudes, and practices regarding deprescribing. Method: A scoping review was conducted following Joaassess healthcaree (JBI) methodology and reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). Primary studies were eligible if they involved nurses, pharmacists or physicians and applied any instrument assessing KAP related to deprescribing, individually or in combination, regardless of setting or country. Nine electronic databases were searched, including two grey literature sources were searched from inception to September 2024, without restrictions on language or publication date using terms related to nurses, pharmacists, physicians, deprescribing, surveys and questionnaires, and health knowledge, attitudes, and practice Study selection and data charting were performed independently by three pairs of reviewers using a standardised extraction form capturing study characteristics, instrument details, KAP domains assessed, and reported measurement properties. Data was synthesised using descriptive statistics and narrative analysis. The review protocol was registered on the Open Science Framework. Results: Of the 3,821 records screened, 49 met the inclusion criteria. Over two-thirds of the included studies were published since 2020 (n = 33, 67.3%). The evidence base was concentrated in high-income countries (n = 36/46, 78.0%; three multi-country studies were not classified by income level), particularly in the Europe and Central Asia region (n = 19, 41.0%), and most often focused solely on physicians, while studies simultaneously involving all three professional groups (physicians, pharmacists, and nurses) were less frequent (n = 8, 16.0%). Instruments commonly assessed multiple KAP domains, especially knowledge, attitudes, and practices combined (n = 12, 30.0%), whereas evidence on psychometric properties was reported in only a minority of studies (n = 13, 26.5%), among these, internal consistency and content validity were the pair most frequently reported together (n = 4, 31.0%). Conclusion: Instruments assessing healthcare professionals’ KAP regarding deprescribing remain limited in scope and psychometric robustness. Expanding interprofessional coverage and strengthening validation efforts are key priorities for advancing research in this field.
- 21 August 2026
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 48 (6) , 2201-2211
Open AccessInstruments for assessing healthcare professionals’ knowledge, attitudes and practices regarding deprescribing: a scoping review
Introduction: Deprescribing is a multiprofessional process which aims to optimize medication use and improve patient safety, in which healthcare professionals' knowledge, attitudes, and practices (KAP) play a central role. The instruments used to assess KAP among nurses, pharmacists and physicians remain poorly characterised in terms of scope and measurement quality. Aim: To map and characterize the instruments used to assess healthcare professionals’ knowledge, attitudes, and practices regarding deprescribing. Method: A scoping review was conducted following Joaassess healthcaree (JBI) methodology and reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). Primary studies were eligible if they involved nurses, pharmacists or physicians and applied any instrument assessing KAP related to deprescribing, individually or in combination, regardless of setting or country. Nine electronic databases were searched, including two grey literature sources were searched from inception to September 2024, without restrictions on language or publication date using terms related to nurses, pharmacists, physicians, deprescribing, surveys and questionnaires, and health knowledge, attitudes, and practice Study selection and data charting were performed independently by three pairs of reviewers using a standardised extraction form capturing study characteristics, instrument details, KAP domains assessed, and reported measurement properties. Data was synthesised using descriptive statistics and narrative analysis. The review protocol was registered on the Open Science Framework. Results: Of the 3,821 records screened, 49 met the inclusion criteria. Over two-thirds of the included studies were published since 2020 (n = 33, 67.3%). The evidence base was concentrated in high-income countries (n = 36/46, 78.0%; three multi-country studies were not classified by income level), particularly in the Europe and Central Asia region (n = 19, 41.0%), and most often focused solely on physicians, while studies simultaneously involving all three professional groups (physicians, pharmacists, and nurses) were less frequent (n = 8, 16.0%). Instruments commonly assessed multiple KAP domains, especially knowledge, attitudes, and practices combined (n = 12, 30.0%), whereas evidence on psychometric properties was reported in only a minority of studies (n = 13, 26.5%), among these, internal consistency and content validity were the pair most frequently reported together (n = 4, 31.0%). Conclusion: Instruments assessing healthcare professionals’ KAP regarding deprescribing remain limited in scope and psychometric robustness. Expanding interprofessional coverage and strengthening validation efforts are key priorities for advancing research in this field.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1)
From Widespread Use to Loss of Effectiveness: The Consequences of Inappropriate Azithromycin Prescriptions During the COVID‐19 Pandemic—A Systematic Review and Meta‐Analysis
Objectives: We are aimed at evaluating whether the widespread use of azithromycin during the COVID‐19 pandemic led to a significant increase in bacterial resistance compared with the prepandemic period and estimating the magnitude of this effect through a systematic review and meta‐analysis. Methods: This systematic review followed the PRISMA 2020 guidelines and Cochrane Handbook (Page,2021). Observational studies published between 2015 and 2025 reporting azithromycin resistance before and after the COVID‐19 pandemic were identified. Odds ratios (ORs) were pooled using a random‐effects model. Methodological quality was assessed using the Newcastle–Ottawa scale. Results: Eight studies met the eligibility criteria and were included in the quantitative synthesis. The meta‐analysis demonstrated a significant increase in azithromycin resistance in the postpandemic period, with a pooled OR of 2.71 (95% CI: 2.04–3.59). Substantial heterogeneity was observed ( I 2 = 73.5 % ), justifying the use of a random‐effects model. Conclusions: The findings provide robust evidence that the excessive and largely empirical use of azithromycin during the COVID‐19 pandemic contributed to a global rise in bacterial resistance. Strengthening antimicrobial stewardship policies is essential to preserve the clinical effectiveness of macrolides during future public health emergencies.
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1)
Open AccessFrom Widespread Use to Loss of Effectiveness: The Consequences of Inappropriate Azithromycin Prescriptions During the COVID‐19 Pandemic—A Systematic Review and Meta‐Analysis
Objectives: We are aimed at evaluating whether the widespread use of azithromycin during the COVID‐19 pandemic led to a significant increase in bacterial resistance compared with the prepandemic period and estimating the magnitude of this effect through a systematic review and meta‐analysis. Methods: This systematic review followed the PRISMA 2020 guidelines and Cochrane Handbook (Page,2021). Observational studies published between 2015 and 2025 reporting azithromycin resistance before and after the COVID‐19 pandemic were identified. Odds ratios (ORs) were pooled using a random‐effects model. Methodological quality was assessed using the Newcastle–Ottawa scale. Results: Eight studies met the eligibility criteria and were included in the quantitative synthesis. The meta‐analysis demonstrated a significant increase in azithromycin resistance in the postpandemic period, with a pooled OR of 2.71 (95% CI: 2.04–3.59). Substantial heterogeneity was observed ( I 2 = 73.5 % ), justifying the use of a random‐effects model. Conclusions: The findings provide robust evidence that the excessive and largely empirical use of azithromycin during the COVID‐19 pandemic contributed to a global rise in bacterial resistance. Strengthening antimicrobial stewardship policies is essential to preserve the clinical effectiveness of macrolides during future public health emergencies.
- Open Access
- 14 March 2024
- Published by Editora UNINGA in Uningá Journal
- Vol. 61, eUJ4570
Humoral anti-SARS-CoV-2 immune response for different strains after Sinovac-CoronaVac and Oxford/AstraZeneca (ChAdOx1-S) full vaccination on a healthcare population in Brazil
COVID-19, caused by the SARS-CoV-2 virus, is a global respiratory syndrome with high mortality rates. Vaccination is currently the only proven method to prevent the disease, although the role of lab data in assessing efficacy remains uncertain. This study aimed to assess spike-binding and neutralizing antibody levels following full vaccination with Oxford/AstraZeneca (ChAdOx1 nCoV-19) or CoronaVac in healthcare workers in southeastern Brazil. ChAdOx1 nCoV-19 and CoronaVac induced IgG antibodies against trimeric spike glycoproteins in 99.5% and 80.9% of individuals, respectively. Neutralizing antibodies were produced against two viral strains groups: variants group 1 (Wuhan-Hu-1, Alpha) and variants group 2 (Beta, Gamma) with neutralization rates of 88.3% and 78.2% for ChAdOx1 nCoV-19, and 68.1% and 48.9% for CoronaVac. No associations were found between neutralizing levels and comorbidities, age, or side effects. A positive correlation was observed between IgG antibody concentrations against trimeric spike glycoproteins and neutralizing levels for both vaccines and variants. These findings indicate that both vaccines induced reasonable levels of neutralizing antibodies against variants group 1, but only ChAdOx1 nCoV-19 maintained acceptable levels against a variant strain. The study suggests that evaluating vaccine responses to different pathogen strains can aid in managing healthcare workforce concerns and improve vaccine selection, thereby enhancing overall vaccination strategies.
- 14 March 2024
- Published by Editora UNINGA in Uningá Journal
- Vol. 61, eUJ4570
Open AccessHumoral anti-SARS-CoV-2 immune response for different strains after Sinovac-CoronaVac and Oxford/AstraZeneca (ChAdOx1-S) full vaccination on a healthcare population in Brazil
COVID-19, caused by the SARS-CoV-2 virus, is a global respiratory syndrome with high mortality rates. Vaccination is currently the only proven method to prevent the disease, although the role of lab data in assessing efficacy remains uncertain. This study aimed to assess spike-binding and neutralizing antibody levels following full vaccination with Oxford/AstraZeneca (ChAdOx1 nCoV-19) or CoronaVac in healthcare workers in southeastern Brazil. ChAdOx1 nCoV-19 and CoronaVac induced IgG antibodies against trimeric spike glycoproteins in 99.5% and 80.9% of individuals, respectively. Neutralizing antibodies were produced against two viral strains groups: variants group 1 (Wuhan-Hu-1, Alpha) and variants group 2 (Beta, Gamma) with neutralization rates of 88.3% and 78.2% for ChAdOx1 nCoV-19, and 68.1% and 48.9% for CoronaVac. No associations were found between neutralizing levels and comorbidities, age, or side effects. A positive correlation was observed between IgG antibody concentrations against trimeric spike glycoproteins and neutralizing levels for both vaccines and variants. These findings indicate that both vaccines induced reasonable levels of neutralizing antibodies against variants group 1, but only ChAdOx1 nCoV-19 maintained acceptable levels against a variant strain. The study suggests that evaluating vaccine responses to different pathogen strains can aid in managing healthcare workforce concerns and improve vaccine selection, thereby enhancing overall vaccination strategies.
- Open Access
- 1 April 2019
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 52 (2) , 92-96
SPECT/CT with 99mTc-sestamibi for the evaluation of skeletal muscle perfusion after electrical muscle stimulation in athletes
Objective: The purpose of this study was to evaluate the effects of electrical muscle stimulation (EMS) on muscles, using 99mTc-sestamibi SPECT/CT. Materials and Methods: We prospectively enrolled 20 consecutive male professional water polo players. The mean age was 25 years (range, 18-36 years). All athletes underwent 99mTc-sestamibi SPECT/CT of the thigh (rectus femoris and vastus medialis muscle groups) before and after EMS. Images were quantified to identify increases in perfusion after EMS. Results: Before EMS, there were no significant differences between the right and left thigh (rectus femoris and vastus medialis muscles) in terms of perfusion (p = 0.4). However, the comparison between the pre- and post-EMS analyses of the same muscle groups showed significant differences in radiotracer uptake (p < 0.001), with a mean increase in perfusion of 128% for the rectus femoris muscle group (95% CI: 0.86-1.61) and 118% for the vastus medialis muscle group (95% CI: 0.96-1.79). Conclusion: 99mTc-sestamibi SPECT/CT is an objective means of evaluating blood flow in muscles submitted to EMS, which appears to promote significant increases in such blood flow.
- 1 April 2019
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 52 (2) , 92-96
Open AccessSPECT/CT with 99mTc-sestamibi for the evaluation of skeletal muscle perfusion after electrical muscle stimulation in athletes
Objective: The purpose of this study was to evaluate the effects of electrical muscle stimulation (EMS) on muscles, using 99mTc-sestamibi SPECT/CT. Materials and Methods: We prospectively enrolled 20 consecutive male professional water polo players. The mean age was 25 years (range, 18-36 years). All athletes underwent 99mTc-sestamibi SPECT/CT of the thigh (rectus femoris and vastus medialis muscle groups) before and after EMS. Images were quantified to identify increases in perfusion after EMS. Results: Before EMS, there were no significant differences between the right and left thigh (rectus femoris and vastus medialis muscles) in terms of perfusion (p = 0.4). However, the comparison between the pre- and post-EMS analyses of the same muscle groups showed significant differences in radiotracer uptake (p < 0.001), with a mean increase in perfusion of 128% for the rectus femoris muscle group (95% CI: 0.86-1.61) and 118% for the vastus medialis muscle group (95% CI: 0.96-1.79). Conclusion: 99mTc-sestamibi SPECT/CT is an objective means of evaluating blood flow in muscles submitted to EMS, which appears to promote significant increases in such blood flow.